Buparvakuon

Yıl 2023, , 61 - 64, 29.12.2023

Muhittin Uslu , Rahmi Canbar

https://doi.org/10.58833/bozokvetsci.1358681

Öz

Theileriosis tropikal ve subtropikal bölgelerde Theileria spp. türlerinin Ixodidae ailesi ait kenelerle nakledilmesi sonucu gelişen bir tür kan protozoonu enfeksiyonudur. Hastalık özellikle ruminantlarda yüksek mortalite ve morbitide ile seyretmektedir. Perakut vakalarda ilk birkaç gün içinde ölümler gözlenirken, akut vakalarda ilk haftalar içinde ölümler gözlendiği bildirilmektedir. Hastalarda ateş, lenfadenopati, solunum güçlüğü, kalp atım sayısında artış, süt veriminde azalma, canlı ağırlık kaybı, abort ve ölümler gözlenmektedir. Hidroksinaftokinon grubu antiprotozoal ilaç olan buparvakuon hastalığın tedavisinde kullanılan en etkili tek ilaçtır. Sığırlarda, theileriosis enfeksiyonuna karşı ilacın 2.5 mg/kg dozunda kas içi kullanımı önerilmekle birlikte hekim tarafından gerekli görüldüğü durumda ise 2-3 gün sonra aynı dozaj rejiminde kullanılabilir. İlacın kullanımı durumunda uygulandığı bölgede lokal reaksiyonlar gelişebildiği, ayrıca aşılarla birlikte ve gebe hayvanlarda kullanımı önerilmemektedir. İlaç genel anlamda güvenli kabul edilmektedir. Hastalığın kenelerle nakil edilmesi nedeni ile tedavi protokolüne bir ektoparaziter ajan eklenmesi tavsiye edilmektedir. Bu derlemede theileriosis tedavisinde buparvakuon kullanımı hakkında bilgiler verilmeye çalışılmıştır.

Anahtar Kelimeler

Buparvakuon, Theileriosis, Hayvan, Türleri

Etik Beyan

-

Destekleyen Kurum

Yok

Proje Numarası

-

Teşekkür

-

BUPARVAQUONE

Öz

Theileriosis is a type of blood protozoan infection caused by the transmission of Theileria spp. species in tropical and subtropical regions by ticks belonging to the Ixodidae family. The disease progresses with high mortality and morbidity especially in ruminants. While deaths are observed in the first few days in peracute cases, it is reported that deaths are observed within the first weeks in acute cases. Fever, lymphadenopathy, respiratory distress, increase in heart rate, decrease in milk yield, weight loss, abortion and death are observed in patients. Buparvaquone, an antiprotozoal drug of the hydroxynaphthoquinone group, is the single most effective drug used in the treatment of the disease. Although it is recommended to use 2.5 mg/kg intramuscularly against theileriosis infection in cattle, it can be used in the same dosage regimen 2-3 days later if deemed necessary by the physician. In case of use of the drug, local reactions may develop in the area where it is applied, and it is not recommended to be used with vaccines and in pregnant animals. The drug is generally considered safe. Since the disease is transmitted by ticks, it is recommended to add an ectoparasitic agent to the treatment protocol. In this review, it has been tried to give information about the use of buparvaquone in the treatment of theileriosis.

Anahtar Kelimeler

Buparvaquone, Theileriosis, Animal, Species

Proje Numarası

-

Kaynakça

• 1. Yazar, E. Veterinary Medicine and Vaccine A to Z. First Edition. İstanbul: Nobel Tıp Kitabevleri, 2018; pp. 66.
• 2. Yazar E. Antiprotozoan Treatment. Yazar E.(Eds). In: Veterinary Medication Guide and Treatment Manual. İstanbul: Nobel Tıp Kitabevleri, 2021; pp. 221-223.
• 3. McHardy N, Pitman-Moore C, Hill. Butalex (buparvaquone): A new therapeutic for theileriosis. Dolan TT.(Eds). In: Recent Developments in the Research and Control of Theileria Annulata: Proceedings of a Workshop Held at ILRAD. Nairobi: The International Laboratory for Research on Animal Diseases (ILRAD), 1992; pp.59-66.
• 4. Ghauri HN, Ijaz M, Farooqi SH, Ali A, Ghaffar A, et al. A comprehensive review on past, present and future aspects of canine theileriosis. Microbial Pathogenesis 2019; 126: 116-122.
• 5. Inci A, Yavuz A, Yildirim A, Düzlü Ö, Bişkin Z. Metastasis in Bovine Theileriosis. Erciyes Üniversitesi Veteriner Fakültesi Dergisi 2012; 9(2): 113-122.
• 6. McDougall S, Hillerton JE, Pegram D. Concentrations of buparvaquone in milk and tissue of dairy cows. New Zealand Veterinary Journal 2016; 64(6): 318-323.
• 7. Ibrahim E, Mohammed SB, El-Ghali A, Salih DA, Hassan SM, et al. Efficacy of Buparvaquone Treatment in Pregnant Cows Infect with Theileria Species in Sudan. Asian Journal of Research in Animal and Veterinary Sciences 2020; 5(1): 29-37.
• 8. Isik N, Ekici OD, Ilhan C, Coskun D. Safety of antitheilerial drug buparvaquone in rams. Acta Scientiae Veterinariae 2018; 46(1): 1547. 9. Ider M, Naseri A, Parlak TM, Zhunushova A, Yazar E. Safety of an antiprotozoal drug combination in sheep. Eurasian Journal of Veterinary Sciences 2020; 36(2): 115-120.
• 10. Gharbi M, Darghouth MA, Elati K, AL‐Hosary AA, Ayadi O, et al. Current status of tropical theileriosis in Northern Africa: A review of recent epidemiological investigations and implications for control. Transboundary and Emerging Diseases 2020; 67(S1): 8-25.
• 11. Yousef SG, El Balkemy FA, El Damaty HM. Mutations in Theileria Annulata Cytochrome B Gene Associated with Buparvaquone Resistance in Cattle, Egypt. Pakistan Veterinary Journal 2020; 40(2): 261-263.
• 12. Gomes J, Bilgic HB, Karagenc T. Theileriosis and tick control management in different mediterranean livestock production systems. Animal Health and Livestock, Mediterranean Perspectives. No:39/2018. Paris: CIHEAM 2018.
• 13. Gokce G, Paşa S, Öcal N. Some blood parameters, blood gases and urine analysis in Theileria infected cattle. Kafkas Üniversitesi Veteriner Fakültesi Dergisi 1998; 4(1-2): 43-47.
• 14. Kizil M, Baydar E, Kizil O. Changes of antioxidant parameters in cattle with theileriosis. Fırat Üniversitesi Sağlık Bilimleri Veteriner Dergisi 2011; 25(2): 53-56.
• 15. Unsuren H, Kurtdede A. Some investigations on the therapy of cattle theileriosis with buparvaquone on the area of Ankara. Ankara Üniversitesi Veteriner Fakültesi Dergisi 1988; 35(1): 47-54.
• 16. Saruhan B, Paşa S. Therapeutic efficacy of buparvaquone (buparvon) in cattle with theileriosis. Turkiye Parazitoloji Dergisi 2008; 32(4): 317-321.
• 17. Gul Y, Aksoy G, Ozdemir H. Elazığ ve çevresinde Theileria annulata ile enfekte sığırların Buparvaquone (Butalex)‘la tedavisi üzerine araştırmalar. Yüzüncü Yıl Üniversitesi Veteriner Fakültesi Dergisi, 1991; 2(1): 97-116.
• 18. Khan A, Ashfaq K, ud Din I, ul Haq R, Jamil M, et al. Bovine theileriosis: Prevalence, estimation of hematological profile and chemotherapy in cattle in Dera Ismail Khan, Khyber Pakhtunkhwa Province, Pakistan. American Academic Scientific Research Journal for Engineering, Technology, and Sciences, 2017; 32(1): 8-17.
• 19. Mbwambo HA, Magwisha HB, Mfinanga JM. Evaluation of buparvaquone (BUTA-Kel™ KELA, Belgium) as a treatment of East Coast fever in cattle, in the peri-urban of Dar Es Salaam city, Tanzania. Veterinary Parasitology 2006; 139(1-3): 67-73.
• 20. Verma AK, Singh SK. Control and therapeutic management of bovine tropical theileriosis in crossbred cattle. Journal of Parasitic Diseases, 2016; 40(1): 208-210.
• 21. Goud KS, Vijayakumar K, Davis KJ, Tresamol PV, Devada KCRK. Efficacy of different treatment regimens against Oriental theileriosis in naturally infected cattle. Indian Journal of Veterinary Medicine 2020; 40(2): 14-19.
• 22. Suthar AN, Prajapati AS, Das B, Patel RM, Pathan AA, et al. Theileriosis in a indigenous Kankrej calf: therapeutic management with aid of blood transfusion. Haryana Veterinarian 2020; 59: 143-145.
• 23. Prasanth CR, Ajithkumar S. Medical management of theileriosis with abomasal impaction in a calf. International Journal of Science, Environment, and Technology 2016; 5(6): 3838-3842.
• 24. Singh S, Sudan V, Sachan P, Srivastava A. Salvage of Theileria infected calves with clinical manifestation of exophthalmia. Journal of Parasitic Diseases 2015; 39(3): 448-451.
• 25. Joshi V, Alam S, Dimri U, Bhanuprakash AG, Gopalakrishnan A, et al. A rare case of Theileria annulata induced corneal opacity in a calf. Journal of Parasitic Diseases 2017; 41(2): 442-445.
• 26. Coşkun D, Yazar E. Chemotherapy. Dik B, Avcı O(Eds.). In: Buffalo Hand Book. Ankara: Güneş Tıp Kitapevleri, 2019; pp. 211-251. 27. Patil NA, Satbige AS. Molecular detection, haematological and therapeutic studies on theileriosis in buffaloes. Buffalo Bulletin 2019; 38(1): 141-146.
• 28. Osman SA, Al-Gaabary MH. Clinical, haematological and therapeutic studies on tropical theileriosis in water buffaloes (Bubalus bubalis) in Egypt. Veterinary Parasitology 2007; 146(3-4): 337-340. https://doi.org/10.1016/j.vetpar.2007.03.012.
• 29. Zia-ur-Rehman, Khan MS, Avais M, Aleem M, Shabbir MZ, et al. Prevalence of theileriosis in sheep in Okara District, Pakistan. Pakistan Journal of Zoology 2010; 42(5): 639-643.
• 30. Baneth G. Antiprotozoal treatment of canine babesiosis. Veterinary Parasitology, 2018; 254: 58-63.
• 31. Maiti SK, Ratre HK, Poyam MR, Hota A, Raghuvanshi PDS. A case report on equine piroplasmosis in a thoroughbred horse from durg, chhattisgarh and its therapeutic management. Haryana Veterinarian, 2021; 60: 114-116.
• 32. Steyl JC, Prozesky L, Stoltsz WH, Lawrence JA. Theileriosis (Cytauxzoonosis) in Roan antelope (Hippotragus equinus): Field exposure to infection and identification of potential vectors. Onderstepoort Journal of Veterinary Research 2012; 79(1): 1-8.
• 33. Mitema ES, Kocan AA, Mukolwe SW, Sangiah S, Sherban D. Activity of buparvaquone against Theileria cervi in white-tailed deer. Veterinary Parasitology 1991; 38(1): 49-53.
• 34. Joshi V, Dimri U, Alam S, Gopalakrishnan A. Buparvaquone therapy in a rock pigeon infected with Haemoproteus columbae showing torticollis. Journal of Parasitic Diseases, 2017; 41(2): 514-516.
• 35. Monteiro LM, Löbenberg R, Barbosa EJ, de Araujo GLB, Sato PK, et al. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences 2022; 169: 106097.
• 36. Borba-Santos LP, Barreto TL, Vila T, Chi KD, dos Santos Monti F, et al. In Vitro and In Vivo Antifungal Activity of Buparvaquone against Sporothrix brasiliensis. Antimicrobial Agents and Chemotherapy, 2021; 65(9): e00699-21.